Abstract: Highly Active Anti-Retroviral Therapy (HAART) is the mainstay in the management of Human Immunodeficiency Virus (HIV) infection. It is important to evaluate the efficacy of new drugs and HAART combinations. This study analysed clinical and virological data of patients on tenofovir/lamivudine/ dolutegravir (TLD) at baseline, 6 months and one year. Level of adherence was 90.0%. Proportion of patients on WHO clinical stage 1 at baseline, 6 months and 12 months was 89.1%, 91.8% and 99.1%, respectively. Proportion of patients who were viral suppression at 6 months and 12 months were 86.4% and 90.0%, respectively. Age ≥35 years was significantly associated with WHO clinical stage 1 at 6 months. Good adherence was significantly associated with viral suppression at 6 months.
Keywords: Tenofovir, lamivudine, dolutegravir, HAART, HIV, WHO staging, viral suppression.
Title: EFFICACY OF TENOFOVIR/LAMIVUDINE/ DOLUTEGRAVIR (TLD) IN THE TREATMENT OF HIV IN A TERTIARY CARE CENTRE IN SOUTH EAST NIGERIA
Author: Chinyerem Cynthia Nwachukwu, Ifeoma Anne Njelita, Gabriel Ifeanyi Eyisi, Chijioke Amara Ezenyeaku, Amaechi Chinedu Nwachukwu, Anthony Agbata
International Journal of Interdisciplinary Research and Innovations
ISSN 2348-1218 (print), ISSN 2348-1226 (online)
Vol. 11, Issue 1, January 2023 - March 2023
Page No: 38-43
Research Publish Journals
Website: www.researchpublish.com
Published Date: 15-February-2023
